News Sentiment

TXG sentiment intelligence

10X Genomics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 61 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Health Information Services Read-through group
Latest close 42.73 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

79/100 classification confidence.

Company focus 61

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

+9.5% over one week, +48.2% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

10x Genomics to Report Second Quarter 2026 Financial Results on August 6, 2026

Market Reaction

Price moving ahead of tone

60/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 79/100 classification
One-week reaction 9.5% Price confirming higher
Trend fit Trend active 48.2% over four weeks
Fair value 73.9% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 12
Neutral 41
Negative 8

Relevance

Why the article matched

Direct first
Direct company coverage 61
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
TradingView 12
Stock Titan 11
Market source 9
simplywall.st 7
PR Newswire 3
Investing.com 3
StockStory 2
Investing.com Nigeria 2

Event Lens

What the news is about

Classified themes
Market update 34
Earnings 19
Analyst action 3
Balance sheet 3
Deals and strategy 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 61
Stock Titan Direct company coverage

TXG (Nasdaq) RSU vesting entries listed on Form 144 with JP Morgan intermediary

TXG (10x Genomics, Inc.) has filed a Form 144 notice detailing proposed sales of Class A Common stock related to multiple RSU vesting events, with JP Morgan Securities LLC identified as an intermediary. The filing specifies various vesting dates between August 2021 and August 202

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 23:58
Source
Stock Titan
Morningstar Direct company coverage

10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group

10x Genomics has acquired Proteintech Genomics, a division specializing in high-plex proteomic solutions for single cell and spatial applications on 10x platforms. This acquisition expands 10x Genomics' capabilities in proteomics and supports its vision for integrating transcript

Tone
Positive 77/100
Event
Deals and strategy
Published
09 Jun 2026 13:00
Source
Morningstar
Stock Titan Direct company coverage

10x Genomics (TXG) awards 8,829 RSUs to company director

10x Genomics director Sarah A. Teichmann was awarded 8,829 restricted stock units (RSUs) of Class A Common Stock. These RSUs were granted at no cash cost and increased her direct holdings to 35,609 shares. The RSUs will vest in quarterly installments, with one-quarter vesting on

Tone
Neutral 50/100
Event
Balance sheet
Published
09 Jun 2026 09:39
Source
Stock Titan
Stock Titan Direct company coverage

10x Genomics (TXG) awards director Kimberly Popovits 8,829 RSUs

10x Genomics (TXG) director Kimberly J. Popovits was granted 8,829 Restricted Stock Units (RSUs) as an equity award, increasing her direct holdings to 37,445 shares. These RSUs will vest quarterly, starting May 21, 2026, contingent on her continued service. The grant is classifie

Tone
Neutral 50/100
Event
Market update
Published
09 Jun 2026 09:39
Source
Stock Titan
Stock Titan Direct company coverage

10x Genomics (TXG) awards 8,829 RSUs to board director

10x Genomics director, John R. Stuelpnagel, was granted 8,829 restricted stock units (RSUs). These RSUs will vest in four equal quarterly installments starting May 21, 2026, provided he remains a service provider. Following this grant, Stuelpnagel holds 368,436 shares of Class A

Tone
Neutral 50/100
Event
Market update
Published
09 Jun 2026 09:39
Source
Stock Titan
Stock Titan Direct company coverage

10x Genomics (TXG) director receives 8,829 RSUs vesting from 2026

10x Genomics director Alan Mateo has been granted 8,829 restricted stock units (RSUs) for Class A Common Stock. These RSUs will vest in four equal quarterly installments starting May 21, 2026, contingent upon his continued service. Following this grant, Mateo's direct holdings in

Tone
Neutral 50/100
Event
Market update
Published
08 Jun 2026 23:39
Source
Stock Titan
Stock Titan Direct company coverage

10x Genomics (TXG) director receives 8,829 RSU grant, lifts holdings

Sridhar Kosaraju, a director at 10x Genomics (TXG), was granted 8,829 Restricted Stock Units (RSUs) as part of a stock-based compensation award. This grant increases his direct holdings to 65,278 shares, with an additional 3,000 shares held indirectly through a family trust. The

Tone
Neutral 50/100
Event
Market update
Published
08 Jun 2026 23:39
Source
Stock Titan
Stock Titan Direct company coverage

10x Genomics (NASDAQ: TXG) grants 8,829 RSUs to director Suliman

10x Genomics director Shehnaaz Suliman has been granted 8,829 restricted stock units (RSUs) of Class A Common Stock, as reported in a recent Form 4 filing. This equity award, which has no cash purchase price, increases her direct holdings to 37,445 shares. The RSUs will vest in f

Tone
Neutral 50/100
Event
Balance sheet
Published
08 Jun 2026 23:39
Source
Stock Titan
Stock Titan Direct company coverage

10x Genomics (NASDAQ: TXG) investors approve full 2026 meeting agenda

10x Genomics (NASDAQ: TXG) shareholders approved all proposals at their 2026 annual meeting, including the election of three Class I directors for three-year terms, the ratification of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026, an

Tone
Neutral 50/100
Event
Market update
Published
08 Jun 2026 20:46
Source
Stock Titan
Investing.com Direct company coverage

10x genomics CEO Serge Saxonov sells $709,057 in shares

Serge Saxonov, CEO of 10x Genomics, sold 28,893 shares of Class A Common Stock across two transactions last week, totaling approximately $709,057. These sales, conducted between $24.4415 and $24.7092 per share, included shares sold to cover tax obligations and those executed via

Tone
Negative 36/100
Event
Market update
Published
30 May 2026 08:10
Source
Investing.com
Investing.com Nigeria Direct company coverage

10x genomics CEO Serge Saxonov sells $709,057 in shares By Investing.com

Serge Saxonov, CEO of 10x Genomics, sold 28,893 shares of Class A Common Stock across two transactions last week, totaling approximately $709,057. These sales were related to tax obligations from restricted stock units and a pre-arranged trading plan. Despite his sales, Saxonov r

Tone
Negative 35/100
Event
Market update
Published
28 May 2026 22:39
Source
Investing.com Nigeria
Investing.com Australia Direct company coverage

10x genomics president Hindson sells $283,399 in company stock By Investing.com

10x Genomics President and Chief Scientific Officer, Benjamin J. Hindson, sold 11,595 shares of company stock totaling $283,399 to cover tax obligations. This sale occurred while TXG stock was trading near its 52-week high after a significant 197% gain, though it appears overvalu

Tone
Neutral 50/100
Event
Market update
Published
28 May 2026 08:02
Source
Investing.com Australia